NeoGenomics, Inc. provided earnings guidance for the year 2024. For the year, the company expects consolidated revenue of $650 million to $660 million, net loss of $72 million to $66 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.08 USD | -0.68% |
|
+0.54% | -19.16% |
28/05 | NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO | CI |
02/05 | North American Morning Briefing : Stock Futures -3- | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.16% | 1.68B | |
-18.89% | 8.49B | |
+65.89% | 4.29B | |
+5.48% | 2.68B | |
-1.93% | 2.63B | |
-57.14% | 1.73B | |
-20.01% | 1.45B | |
+15.38% | 1.19B | |
-50.40% | 1.01B | |
+14.04% | 939M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024